Alnylam Pharmaceuticals, Inc. (ALNY)
Automate Your Wheel Strategy on ALNY
With Tiblio's Option Bot, you can configure your own wheel strategy including ALNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALNY
- Rev/Share 28.0865
- Book/Share 5.9681
- PB 55.1849
- Debt/Equity 1.6199
- CurrentRatio 2.7624
- ROIC 0.1374
- MktCap 43679384721.0
- FreeCF/Share 3.5194
- PFCF 93.8569
- PE 138.808
- Debt/Assets 0.2574
- DivYield 0
- ROE 0.9035
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ALNY | Barclays | -- | Overweight | -- | $527 | Jan. 28, 2026 |
| Resumed | ALNY | Oppenheimer | -- | Outperform | -- | $500 | Jan. 7, 2026 |
| Upgrade | ALNY | Wolfe Research | Underperform | Peer Perform | -- | -- | Aug. 4, 2025 |
| Upgrade | ALNY | Oppenheimer | Perform | Outperform | -- | $490 | Aug. 4, 2025 |
| Resumed | ALNY | Raymond James | -- | Outperform | -- | $370 | July 30, 2025 |
| Initiation | ALNY | Truist | -- | Buy | -- | $385 | July 21, 2025 |
| Initiation | ALNY | Redburn Atlantic | -- | Buy | -- | $353 | March 31, 2025 |
| Upgrade | ALNY | JP Morgan | Neutral | Overweight | $280 | $328 | March 24, 2025 |
| Initiation | ALNY | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Upgrade | ALNY | Goldman | Neutral | Buy | $198 | $370 | Aug. 16, 2024 |
News
Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations
Published: February 13, 2026 by: Seeking Alpha
Sentiment: Positive
Alnylam Pharmaceuticals has declined nearly 40% from its all-time high, pressured by near-term TTR market dynamics and longer-term profitability concerns. The TTR business will likely remain "noisy" in the first half of 2026, but Amvuttra continues to gain share, and management guidance for 2026 was above expectations. Management alarmed the Street earlier this year with long-term spending guidance that was considerably higher than expected; management continues to prioritize R&D to realize the company's full long-term potential.
Read More
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
Alnylam tops Q4 earnings estimates but misses on sales despite 85% revenue growth, as booming Amvuttra demand fails to lift shares.
Read More
Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.06 per share a year ago.
Read More
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Alnylam (ALNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Read More
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
Published: January 05, 2026 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the presentation, the Company will unveil its new five-year strategy, which will guide the Company's next phase of gro.
Read More
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Published: December 19, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Read More
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing
Published: December 01, 2025 by: Barrons
Sentiment: Positive
Those four companies, culled from a list drawn up by KBW analyst Shreyank Gandhi, are among the largest not in the index.
Read More
What's Going On With Alnylam Stock On Friday?
Published: November 28, 2025 by: Benzinga
Sentiment: Neutral
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stock is trading higher on Friday, with no news to justify the movement.
Read More
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Alnylam Pharmaceuticals (ALNY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Read More
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Alnylam Pharmaceuticals, Inc. ( ALNY ) UBS Global Healthcare Conference 2025 November 10, 2025 10:15 AM EST Company Participants Jeffrey Poulton - CFO & Executive VP John Vest - Senior Vice President of Clinical Research Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.
Read More
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Read More
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2025 Earnings Call Transcript
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Alnylam Pharmaceuticals, Inc. ( ALNY ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Pushkal Garg - EVP of Development & Medical Affairs and Chief Research & Dev. Officer Jeffrey Poulton - CFO & Executive VP Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Jessica Fye …
Read More
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to a loss of $0.5 per share a year ago.
Read More
Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Why Alnylam (ALNY) Might be Well Poised for a Surge
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Read More
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Alnylam Pharmaceuticals (ALNY) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
Read More
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Read More
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 8:00 AM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Read More
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Published: September 18, 2025 by: PRNewsWire
Sentiment: Neutral
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO , Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD).
Read More
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Read More
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study.
Read More
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
Read More
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025 at 1:45 pm ET in Boston Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:05 pm ET in New York City Bernstein Insights: Healthcare Leaders and Disru.
Read More
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
Published: August 11, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new data from its hypertension and transthyretin amyloidosis (ATTR) programs at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place in Madrid, Spain, from August 29 - September 1, 2025. These presentations will highlight the potential of RNAi therapeutics to transform the treatment of cardiovascular diseas.
Read More
About Alnylam Pharmaceuticals, Inc. (ALNY)
- IPO Date 2004-06-01
- Website https://www.alnylam.com
- Industry Biotechnology
- CEO Yvonne L. Greenstreet
- Employees 2230